医用胶原蛋白调节TNF-α治疗变应性接触性皮炎的作用机制研究

摘要

Objective To study the adjust TNF-α of medical collagen treats ACD and mechanism.Methods Duplication ACD models were made,the mouse skin was smeared with this medical collagen for about 14 days as a therapy,ear tissue were given histopathological examination,ELISA was used to test the levels of TNF-α,IL-2 inflammatory mediators.Results Compared with pre attack,ear allergy were very obvious in all group after attack 12,24 h (P ＜ 0.01).Compared with blank control group,the ear allergy increased in medical collagen low does group after attack 12 h (P ＜0.05),the ear allergy increased in model control group after attack 24 h (P ＜ 0.05).Compared with model control group,the ear allergy reduced in medical collagen low,middle,high does group after attack 24h (P ＜ 0.05).Compared with blank control group,inflammatory cells of the right ear increased in all group mouse (P ＜ 0.05).Compared with model control group,inflammatory cells of the right ear reduced in dexamethasone control group,medical collagen low,high does group (P ＜ 0.05 or P ＜ 0.01).Compared with blank control group,the left and fight ear piece thickness difference enlarged obviously in model control group,dexamethasone control group,medical collagen middle and high does group (P ＜ 0.01).Compared with model control group,the left and right ear piece thick ness difference decreased in medical collagen low does group mouse (P ＜ 0.05).Compared with blank control group,TNF-α level increased obviously in model control group and medical collagen low does group mouse (P ＜ 0.05).Compared with model control group,TNF-α's level reduced in dexamethasone control group and medical collagen high does group mouse (P ＜ 0.01 or P ＜ 0.05).Meanwhile,this therapy did not influenced the animals’ weight.Conclusion Medical collagen can be a certain medical treatment for ACD,but it may connect with the adjust of the level of TNF-α and then decrease of the ear inflammation.%目的 研究医用胶原蛋白调节TNF-α治疗变应性接触性皮炎的作用及机制.方法 制造二硝基氟苯致小鼠变应性接触性皮炎模型,医用胶原蛋白连续14 d涂抹动物皮肤,对耳部组织进行病理学检查,应用ELISA方法测试TNF-α、IL-2等炎症介质.结果 与攻击前比较,各组小鼠在攻击后12、24 h均出现十分明显的耳变态反应(P＜0.01);与空白对照组比较,医用胶原蛋白低剂量组小鼠在攻击后12h时耳变态反应评分升高(P＜0.05),在攻击后24 h时模型对照组耳变态反应评分明显升高(P＜0.05);与模型对照组比较,在攻击后24 h时医用胶原蛋白低、中和高剂量组小鼠的耳变态反应评分均降低(P＜0.05).与空白对照组比较,模型对照组、地塞米松对照组和医用胶原蛋白低、中、高剂量组小鼠右耳片的炎症细胞数明显地增加(P＜0.01);与模型对照组比较,地塞米松对照组和医用胶原蛋白低、高剂量组小鼠右耳片的炎症细胞数减少(P＜ 0.05或P＜0.01).与空白对照组比较,模型对照组、地塞米松对照组和医用胶原蛋白中、高剂量组小鼠左右耳片厚度差明显地变大(P＜0.01).与模型对照组比较,医用胶原蛋白低剂量组小鼠左右耳片厚度差变小(P＜0.05);与空白对照组比较,模型对照组和医用胶原蛋白低剂量组小鼠血清中炎症因子TNF-α含量明显地升高(P＜0.01);与模型对照组比较,地塞米松对照组小鼠血清中炎症因子TNF-α含量明显地降低(P＜0.01),医用胶原蛋白高剂量组小鼠血清中炎症因子TNF-α含量明显降低(P＜ 0.05);对动物体重没有明显影响.结论 医用胶原蛋白对变应性接触性皮炎有明显的治疗作用,可能通过调节血清中TNF-α进而减轻耳部炎性反应有关.